Bisacodyl
Identification
- Name
- Bisacodyl
- Accession Number
- DB09020
- Description
Bisacodyl is an organic stimulant laxative that acts directly on the colon to promote bowel movement. Bisacodyl is prescribed for constipation, neurogenic bowel dysfunction, and bowel preparation before medical examinations.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Bisacodyl (DB09020)
- Weight
- Average: 361.3906
Monoisotopic: 361.131408101 - Chemical Formula
- C22H19NO4
- Synonyms
- Bisacodilo
- Bisacodyl
- Bisacodyle
- Bisacodylum
- Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
- External IDs
- LA 96 a
- LA96a
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Indicated for cleansing of the colon as a preparation for colonoscopy in adults.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Bisacodyl is hydrolyzed by intestinal brush border enzymes and colonic bacteria to form an active metabolite [bis-(p-hydroxyphenyl) pyridyl-2 methane; (BHPM)] that acts directly on the colonic mucosa to produce colonic peristalsis.
- Mechanism of action
Induces diarrhea which cleanses the colon.
- Absorption
15%
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic (CYP450-mediated).
- Route of elimination
- Not Available
- Half-life
16 hours
- Clearance
primarily in the feces, systemically absorbed drug is excreted in the urine.
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Bisacodyl. Aclidinium The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Bisacodyl is combined with Alloin. Almasilate The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Almasilate. Aluminium The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium. Aluminium phosphate The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Bisacodyl. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take separate from antacids. Take at least 1 hour before or after antacids and milk.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Active Moieties
Name Kind UNII CAS InChI Key Deacetylbisacodyl unknown R09078E41Y 603-41-8 LJROKJGQSPMTKB-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Bisalax (Actavis) / Bolax (Unifarma) / Boots Constipation Relief (Boots) / Derderance (Nisshin Seiyaku) / Dulco-Lax (Boehringer Ingelheim) / Dulcolaxo (Boehringer Ingelheim) / Fleet Laxative (Baxter) / Florisan (Boehringer Ingelheim) / Laxitab (Ranbaxy) / Reliable Gentle Laxative Tablets (Teva) / Spirolax / Verecolene C.M. (GlaxoSmithKline)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bisacodyl Tablet 5 mg/1 Oral Remedy Repack 2010-08-04 2012-07-01 US 
Magic Bullet Laxative Suppository Suppository Rectal Smordins Dispensary Ltd. Not applicable Not applicable Canada 
Soflax EX Micro-enema Enema; Suspension Rectal Pharmascience Inc Not applicable Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ag-bisacodyl EC Tablet Oral Angita Pharma Inc. Not applicable Not applicable Canada Alophen Tablet, coated 5 mg/1 Oral Numark Brands, Inc 1907-04-15 Not applicable US Alophen Tablets Tablet, delayed release Oral Numark Laboratories, Inc. 1998-08-31 2009-07-31 Canada Apo-bisacodyl Tablet, delayed release Oral Apotex Corporation 1982-12-31 Not applicable Canada Apo-bisacodyl Sup 10mg Suppository Rectal Apotex Corporation 1988-12-31 Not applicable Canada Avedana Gentle Laxative Suppository 10 mg/1 Rectal Unipack, Inc. 2017-09-17 Not applicable US Becolax Tablets Tablet, delayed release Oral Viva Pharmaceutical Inc. Not applicable Not applicable Canada Best Choice Bisacodyl Laxative Tablet, coated 5 mg/1 Oral Best Choice (Valu Merchandisers Company) 2012-11-02 Not applicable US BET-R-PREP Bisacodyl Tablet 5 mg/1 Topical Satius Pharmaceuticals, Llc 2017-11-18 Not applicable US Bisac-Evac Suppository 10 mg/1 Rectal Cardinal Health 2011-06-06 2019-07-31 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bekunis Dragees Bisacodyl (5 mg) + Sennosides (60 mg) + Sennosides (20 mg) + Sennosides (25 mg) Tablet Oral Roha Arzneimittel Gmbh 1974-12-31 2009-07-02 Canada Bi-peglyte Bisacodyl (5 mg) + Polyethylene glycol (59.55 g) + Potassium chloride (0.76 g) + Sodium bicarbonate (1.69 g) + Sodium chloride (1.46 g) + Sodium sulfate (5.74 g) Kit; Powder, for solution; Tablet, delayed release Oral Pendopharm Division Of Pharmascience Inc 2010-06-06 Not applicable Canada Bicholate Lilas Bisacodyl (5 mg) + Aloe Vera Leaf (12 mg) + Frangula purshiana bark (30 mg) + Sodium taurocholate (60 mg) Tablet Oral Sabex Inc 1998-10-28 2009-11-24 Canada Dulcolax Bisacodyl (5 mg/1) + Bisacodyl (10 mg/1) Kit Oral; Rectal Boehringer Ingelheim 2003-04-01 2014-08-31 US Dulcolax Bisacodyl (5 mg/1) + Bisacodyl (10 mg/1) Kit Oral; Rectal Boehringer Ingelheim 2003-04-01 2014-08-31 US Dyrax-Q Tab Bisacodyl (5 mg/161mg) + Docusate sodium (16.75 mg/161mg) Tablet Oral Cho-A Pharm.Co.,Ltd. 2019-10-25 Not applicable US GaviLyte-H and Bisacodyl Bisacodyl (5 mg/1) + Polyethylene glycol (210 g/2L) + Potassium chloride (0.74 g/2L) + Sodium bicarbonate (2.86 g/2L) + Sodium chloride (5.6 g/2L) Kit Oral Lupin Pharmaceuticals, Inc. 2015-04-21 Not applicable US Gentlax S Bisacodyl (5 mg) + Docusate sodium (50 mg) Tablet Oral Purdue Pharma 2004-10-12 2011-08-04 Canada HalfLytely and Bisacodyl Bisacodyl (5 mg/1) + Polyethylene glycol (210 g/2L) + Potassium chloride (0.74 g/2L) + Sodium bicarbonate (2.86 g/2L) + Sodium chloride (5.60 g/2L) Kit Oral Braintree Laboratories 2006-12-31 2012-12-31 US HalfLytely and Bisacodyl Bisacodyl (5 mg/1) + Polyethylene glycol (210 g/2L) + Potassium chloride (0.74 g/2L) + Sodium bicarbonate (2.86 g/2L) + Sodium chloride (5.60 g/2L) Kit Oral Braintree Laboratories 2006-12-31 2012-12-31 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bisacodyl Bisacodyl (5 mg/1) Tablet Oral Cardinal Health 2011-06-02 2011-10-31 US Bisacodyl Bisacodyl (10 mg/1) Suppository Rectal Physicians Total Care, Inc. 2003-09-04 2013-01-15 US Bisacodyl Bisacodyl (5 mg/1) Tablet Oral Remedy Repack 2010-08-04 2012-07-01 US PCP 100 Kit Bisacodyl (5 mg/1) + Magnesium citrate (1.745 g/29.6mL) + Metoclopramide hydrochloride (10 mg/1) + Petrolatum (0.76 g/1g) + Polyethylene glycol (17 g/17g) Kit Oral Asclemed Usa, Inc. 2014-01-02 Not applicable US
Categories
- ATC Codes
- A06AB52 — Bisacodyl, combinations
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Phenol esters / Phenoxy compounds / Pyridines and derivatives / Dicarboxylic acids and derivatives / Heteroaromatic compounds / Carboxylic acid esters / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides show 2 more
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Diphenylmethane / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound show 9 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 10X0709Y6I
- CAS number
- 603-50-9
- InChI Key
- KHOITXIGCFIULA-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3
- IUPAC Name
- 4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetate
- SMILES
- CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1
References
- Synthesis Reference
U.S. Patent 2,764,590.
- General References
- Stiens SA, Luttrel W, Binard JE: Polyethylene glycol versus vegetable oil based bisacodyl suppositories to initiate side-lying bowel care: a clinical trial in persons with spinal cord injury. Spinal Cord. 1998 Nov;36(11):777-81. [PubMed:9848486]
- Wexner SD, Beck DE, Baron TH, Fanelli RD, Hyman N, Shen B, Wasco KE: A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc. 2006 Jun;63(7):894-909. [PubMed:16733101]
- Kudo K, Miyazaki C, Kadoya R, Imamura T, Jitsufuchi N, Ikeda N: Laxative poisoning: toxicological analysis of bisacodyl and its metabolite in urine, serum, and stool. J Anal Toxicol. 1998 Jul-Aug;22(4):274-8. [PubMed:9681329]
- External Links
- AHFS Codes
- 56:12.00 — Cathartics and Laxatives
- FDA label
- Download (62.7 KB)
- MSDS
- Download (495 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Bowel preparation therapy 1 4 Completed Not Available Colonoscopy 1 4 Completed Diagnostic Bowel Cleansing Quality 1 4 Completed Other Chronic Constipation 1 4 Completed Prevention Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Prevention Thoracoabdominal Aortic Aneurysms 1 4 Completed Supportive Care Colonic Motility Index / Constipation 1 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Colonoscopy 6 4 Completed Treatment Colonoscopy Preparation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suppository Rectal 2 MG Tablet, delayed release Oral 5 mg Tablet, film coated Oral 3 mg Tablet Topical 5 mg/1 Kit; powder, for solution; tablet, delayed release Oral Tablet, delayed release Oral 5 m Suppository Rectal 0.01 g/2g Tablet, delayed release Oral 5 mg/1 Suppository Rectal 10 mg/1 Tablet, coated Oral 5 mg Suppository Rectal Kit Oral; Rectal Tablet, coated Oral 5 mg/1 Tablet, delayed release; tablet, film coated Oral 5 MG Suspension Rectal Suppository Rectal 0.01 g Tablet 5 mg Tablet Oral Pill Oral 5 mg/5mg Tablet Oral 5 mg/5mg Enema Rectal 10 mg/30mL Kit Oral Suppository Rectal 5 mg Suppository Rectal 10 mg Suppository Rectal 10 mg/ml Tablet, film coated Oral 5 mg Tablet Oral 5 MG Tablet Oral Suppository Rectal 10 mg/2000mg Tablet, delayed release Oral Enema; suspension Rectal Suppository Rectal 10 MG/G Tablet Oral 5 mg/1 Capsule, gelatin coated Oral 5 mg/1 Tablet, film coated Oral 5 mg/1 Tablet, sugar coated Oral 5 mg/1 Tablet, coated Oral Tablet, sugar coated Oral Tablet, coated Oral Capsule - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US2764590 No 1953-03-16 1973-03-16 US US7291324 No 2007-11-06 2022-10-22 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 138 U.S. Patent 2,764,590. - Predicted Properties
Property Value Source Water Solubility 0.00127 mg/mL ALOGPS logP 4.71 ALOGPS logP 3.61 ChemAxon logS -5.5 ALOGPS pKa (Strongest Basic) 4.08 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 65.49 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 100.15 m3·mol-1 ChemAxon Polarizability 38.48 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-03e9-0619000000-408a755e5a908f9651a8 MS/MS Spectrum - , positive LC-MS/MS splash10-001i-2900000000-44bd4ec7df3de8de29aa
Drug created on June 24, 2014 17:03 / Updated on February 24, 2021 19:34